Literature DB >> 6411107

Pharmacokinetics of valproic acid in young and elderly subjects.

S M Bryson, N Verma, P J Scott, P C Rubin.   

Abstract

The disposition of valproic acid was studied following single dose intravenous administration in seven young male volunteers aged 20-35 years and six elderly male in-patients aged 75-87 years. Following administration of 400 mg sodium valproate, blood samples were collected for 48 h and valproic acid concentrations analysed by enzymatic immunoassay. The median elimination half-life was 7.2 h in the young subjects but 14.9 h in the elderly patients (P less than 0.01). However, clearance did not differ significantly between groups, the values for young and old being 0.69 and 0.58 1/h respectively. The prolonged half-life resulted from a greater volume of distribution in the elderly. The median values (1/kg) for young and old were 0.13 and 0.19 respectively (P less than 0.01). These pharmacokinetic changes are unlikely to be of clinical importance.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6411107      PMCID: PMC1427943          DOI: 10.1111/j.1365-2125.1983.tb02151.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

Review 1.  Clinical pharmacokinetics of valproic acid.

Authors:  R Gugler; G E von Unruh
Journal:  Clin Pharmacokinet       Date:  1980 Jan-Feb       Impact factor: 6.447

Review 2.  Drug therapy: drug disposition in old age.

Authors:  D J Greenblatt; E M Sellers; R I Shader
Journal:  N Engl J Med       Date:  1982-05-06       Impact factor: 91.245

3.  Atenolol disposition in young and elderly subjects.

Authors:  P C Rubin; P J Scott; K McLean; A Pearson; D Ross; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

4.  Prazosin disposition in young and elderly subjects.

Authors:  P C Rubin; P J Scott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

  4 in total
  16 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Treatment recommendations for anticonvulsant drug therapy in the older patient.

Authors:  P D Swanson
Journal:  Drugs Aging       Date:  1992 Mar-Apr       Impact factor: 3.923

Review 3.  Anticonvulsant therapy in aged patients. Clinical pharmacokinetic considerations.

Authors:  I Bernus; R G Dickinson; W D Hooper; M J Eadie
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

Review 4.  Epilepsy in the elderly.

Authors:  Ilo E Leppik; Angela K Birnbaum
Journal:  Ann N Y Acad Sci       Date:  2010-01       Impact factor: 5.691

Review 5.  Treating epilepsy in the elderly: safety considerations.

Authors:  S Arroyo; G Kramer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  Variability of carbamazepine and valproate concentrations in elderly nursing home residents.

Authors:  Angela K Birnbaum; Jeannine M Conway; Melissa A Strege; Ilo E Leppik
Journal:  Epilepsy Res       Date:  2012-03-30       Impact factor: 3.045

Review 7.  Drug treatment of epilepsy in elderly people: focus on valproic Acid.

Authors:  Linda J Stephen
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 8.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

9.  Pharmacokinetics of valproic acid in the elderly.

Authors:  E Perucca; R Grimaldi; G Gatti; S Pirracchio; F Crema; G M Frigo
Journal:  Br J Clin Pharmacol       Date:  1984-06       Impact factor: 4.335

10.  Increased sensitivity to the anticonvulsant effect of valproate in aging BN/BiRij rats.

Authors:  A M Stijnen; S Hovinga; M W Langemeijer; A Hoogerkamp; C F van Bezooijen; M Danhof
Journal:  Pharm Res       Date:  1993-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.